http://rdf.ncbi.nlm.nih.gov/pubchem/reference/31670797

Outgoing Links

Predicate Object
contentType Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't
endingPage 311
issn 1551-7144
issueIdentifier 2
pageRange 301-311
publicationName Contemporary Clinical Trials
startingPage 301
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_f8202d157d94677ba5266937ff9542bf
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_9c6944f585f1a9d47020920e349ec6a1
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_9074157bcb1fa24542b38d17a93a5a36
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_4ddd06f378bf64f0829f4770f1c61cd6
bibliographicCitation Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Calder PC, Byrne CD; WELCOME Trial Investigators. Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected]. Contemp Clin Trials. 2014 Mar;37(2):301–11. doi: 10.1016/j.cct.2014.02.002. PMID: 24556343.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e823f994252f48e4ba62914b6ad7e115
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_52506acce7816eb95624e096143e25b1
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f6c8750acead96c5eae5ae2dd5fb923e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bcd797c3a21a18aac60af081258a9709
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1818a4847994eacc21cd57c55ef49a8c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1b1aeb438284aa183ed2e60b3a1d04c6
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_194226cb7e4f23a48023f392c2f0a762
date 201403
identifier https://pubmed.ncbi.nlm.nih.gov/24556343
https://doi.org/10.1016/j.cct.2014.02.002
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/32406
https://portal.issn.org/resource/ISSN/1551-7144
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected]
discusses http://id.nlm.nih.gov/mesh/M0359442
http://id.nlm.nih.gov/mesh/M0023752
http://id.nlm.nih.gov/mesh/M0023259
http://id.nlm.nih.gov/mesh/M0023885
http://id.nlm.nih.gov/mesh/M0006701
http://id.nlm.nih.gov/mesh/M0006823
http://id.nlm.nih.gov/mesh/M0016959
http://id.nlm.nih.gov/mesh/M000605827
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D015525Q000627
http://id.nlm.nih.gov/mesh/D004281Q000627
http://id.nlm.nih.gov/mesh/D065626Q000188
http://id.nlm.nih.gov/mesh/D015118Q000627
http://id.nlm.nih.gov/mesh/D012107
http://id.nlm.nih.gov/mesh/D019587
hasSubjectTerm http://id.nlm.nih.gov/mesh/D010938
http://id.nlm.nih.gov/mesh/D008099Q000503
http://id.nlm.nih.gov/mesh/D010809
http://id.nlm.nih.gov/mesh/D006334
http://id.nlm.nih.gov/mesh/D012307
http://id.nlm.nih.gov/mesh/D015415
http://id.nlm.nih.gov/mesh/D000328
http://id.nlm.nih.gov/mesh/D065626Q000503
http://id.nlm.nih.gov/mesh/D004338
http://id.nlm.nih.gov/mesh/D004311
http://id.nlm.nih.gov/mesh/D000069463
http://id.nlm.nih.gov/mesh/D008103Q000503
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D004032
http://id.nlm.nih.gov/mesh/D015444
http://id.nlm.nih.gov/mesh/D001837
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7998
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7708
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11303
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9831414
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8345
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7444
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11475
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7181

Showing number of triples: 1 to 66 of 66.